Sophie Schuind
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sophie Schuind has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Fabio Silvio Taccone
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium
2 shared publications - Airton Leonardo de Oliveira Manoel
Department of Surgery, Trauma Surgery, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar
1 shared publication - Ali Msheik
Neurosurgery, Neuroscience Institute, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Anas Hachlouf
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Route de Lennik, 808, 1070 Bruxelles, Belgium
1 shared publication - Chiara Mabiglia
Department of Radiology, Hôpital Universitaire de Bruxelles (HUB)-Erasme, 1070 Brussels, Belgium
1 shared publication - Claudia Stella
Department of Intensive Care, Hôpital Universitaire de Bruxelles (HUB) Université Libre de Bruxelles (ULB) Bruxelles Belgium
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Surgery for intracerebral hemorrhage: new evidence and changing perspectives
Spontaneous intracerebral hemorrhage (ICH) remains the most devastating form of stroke, with limited evidence supporting surgical intervention. Traditional
- 1 December 2025
- Published by Springer Nature in Critical Care
- Vol. 30 (1)
Open AccessSurgery for intracerebral hemorrhage: new evidence and changing perspectives
Spontaneous intracerebral hemorrhage (ICH) remains the most devastating form of stroke, with limited evidence supporting surgical intervention. Traditional
- Open Access
- 30 June 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (7) , 1536
Successful Treatment of Brain Abscess Caused by Nocardia farcinica with Combination Therapy Despite Discrepancies in In Vitro Results: A Case Report and Review of Diagnostic and Therapeutic Challenges
Nocardia spp. is an environmental Gram-positive bacterium able to cause infections in humans, predominantly of an opportunistic nature. Nocardial brain abscesses are rare and result from dissemination from another primary lesion, mainly observed in immunocompromised hosts. The diagnosis of nocardiosis relies on direct examination and bacterial culture, but antimicrobial susceptibility testing (AST) remains controversial due to technical challenges, limited standardization, and a paucity of studies correlating in vitro susceptibility with clinical efficacy. Management is challenging and usually based on expert opinion, as robust evidence is limited. In this case report, we describe an immunocompromised patient with a Nocardia farcinica brain abscess who achieved clinical resolution following combination therapy that included ceftriaxone, despite in vitro resistance, illustrating the complexities in interpreting AST and guiding treatment decisions in rare infections.
- 30 June 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (7) , 1536
Open AccessSuccessful Treatment of Brain Abscess Caused by Nocardia farcinica with Combination Therapy Despite Discrepancies in In Vitro Results: A Case Report and Review of Diagnostic and Therapeutic Challenges
Nocardia spp. is an environmental Gram-positive bacterium able to cause infections in humans, predominantly of an opportunistic nature. Nocardial brain abscesses are rare and result from dissemination from another primary lesion, mainly observed in immunocompromised hosts. The diagnosis of nocardiosis relies on direct examination and bacterial culture, but antimicrobial susceptibility testing (AST) remains controversial due to technical challenges, limited standardization, and a paucity of studies correlating in vitro susceptibility with clinical efficacy. Management is challenging and usually based on expert opinion, as robust evidence is limited. In this case report, we describe an immunocompromised patient with a Nocardia farcinica brain abscess who achieved clinical resolution following combination therapy that included ceftriaxone, despite in vitro resistance, illustrating the complexities in interpreting AST and guiding treatment decisions in rare infections.
- Open Access
- 6 December 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (12) , 1678
The Effects of Acetazolamide on Cerebral Hemodynamics in Adult Patients with an Acute Brain Injury: A Systematic Review
Background: Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme expressed in different cells of the central nervous system (CNS) and involved in the regulation of cerebral blood flow (CBF). The aim of this review was to understand the effects of acetazolamide on CBF, intracranial pressure (ICP) and brain tissue oxygenation (PbtO2) after an acute brain injury (ABI). Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA), we performed a comprehensive, computer-based, literature research on the PubMed platform to identify studies that have reported the effects on CBF, ICP, or PbtO2 of acetazolamide administered either for therapeutic or diagnostic purposes in patients with subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, and hypoxic-ischemic encephalopathy. Results: From the initial search, 3430 records were identified and, through data selection, 11 of them were included for the qualitative analysis. No data on the effect of acetazolamide on ICP or PbtO2 were found. Cerebral vasomotor reactivity (VMR—i.e., the changing in vascular tone due to a vasoactive substance) to acetazolamide tends to change during the evolution of ABI, with the nadir occurring during the subacute stage. Moreover, VMR reduction was correlated with clinical outcome. Conclusions: This systematic review showed that the available studies on the effects of acetazolamide on brain hemodynamics in patients with ABI are scarce. Further research is required to better understand the potential role of this drug in ABI patients.
- 6 December 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (12) , 1678
Open AccessThe Effects of Acetazolamide on Cerebral Hemodynamics in Adult Patients with an Acute Brain Injury: A Systematic Review
Background: Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme expressed in different cells of the central nervous system (CNS) and involved in the regulation of cerebral blood flow (CBF). The aim of this review was to understand the effects of acetazolamide on CBF, intracranial pressure (ICP) and brain tissue oxygenation (PbtO2) after an acute brain injury (ABI). Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA), we performed a comprehensive, computer-based, literature research on the PubMed platform to identify studies that have reported the effects on CBF, ICP, or PbtO2 of acetazolamide administered either for therapeutic or diagnostic purposes in patients with subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, and hypoxic-ischemic encephalopathy. Results: From the initial search, 3430 records were identified and, through data selection, 11 of them were included for the qualitative analysis. No data on the effect of acetazolamide on ICP or PbtO2 were found. Cerebral vasomotor reactivity (VMR—i.e., the changing in vascular tone due to a vasoactive substance) to acetazolamide tends to change during the evolution of ABI, with the nadir occurring during the subacute stage. Moreover, VMR reduction was correlated with clinical outcome. Conclusions: This systematic review showed that the available studies on the effects of acetazolamide on brain hemodynamics in patients with ABI are scarce. Further research is required to better understand the potential role of this drug in ABI patients.